Idiopathic thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA) are ideal models to study the efficacy and mechanism of immunosuppressive therapy in autoimmune diseases. We have reported the value of danazol, an attenuated androgen, in ITP and more recently its benefit in AIHA. Our long-range objectives are to delineate the mechanism(s) of action of danazol and thereby develop an effective and safe treatment for ITP and AIHA, based on the use of sex hormones. Hormonal manipulation of autoimmunity in humans has not been studied in depth. Therefore the knowledge gained from this study can be applicable to other autoimmune diseases of man.
Specific aims are (1) to estimate response rates and side effects of danazol compared to glucocorticoids, (2) to assess its value as an alternative to long-term glucocorticoid therapy and splenectomy, and (3) to study its mechanism of action based on the hypothesis that danazol induces remission by either restoring the imbalance in T cell subsets or by inhibiting complement activation. The prospective randomized protocol of ITP is designed to achieve these goals. Patients will be randomized initially to either danazol or prednisone therapy. If they fail in one, they will receive the other in the next phase and both if neither of them induces remission. Specimens before and during danazol therapy will be collected from patients to monitor antibody levels, T cell subsets, lymphocyte functions and complement components. Data will be analyzed to determine whether danazol inhibits antibody production, MPS function, T cell function or the complement system. Such immune alterations will be correlated with clinical responses. Laboratory investigations will examine the action of danazol on the immune system focusing on three major areas: the effects of danazol on (1) lymphocyte function -a) in vitro action of danazol on normal lymphocyte function (blastogenesis, suppressor cell activity-spontaneous and inducible)-b) in vivo effects on patient's lymphocytes collected before and during therapy; (2) complement system-a) in vitro effects on the complement system in normal sera b) in vivo effects on sera drawn from patients before and during danazol therapy; and (3) modulation of Fc and C3b receptors of monocyte.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK033813-04
Application #
3232213
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1985-09-05
Project End
1989-12-31
Budget Start
1988-09-01
Budget End
1989-12-31
Support Year
4
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Miami School of Medicine
Department
Type
Schools of Medicine
DUNS #
City
Miami
State
FL
Country
United States
Zip Code
33101
Rocha, R; Horstman, L; Ahn, Y S et al. (1991) Danazol therapy for cyclic thrombocytopenia. Am J Hematol 36:140-3
Ahn, Y S (1990) Efficacy of danazol in hematologic disorders. Acta Haematol 84:122-9
Ahn, Y S; Fernandez, L F; Kim, C I et al. (1989) Danazol therapy renders red cells resistant to osmotic lysis. FASEB J 3:157-62
Mylvaganam, R; Ahn, Y S; Sprinz, P G et al. (1989) Sex difference in the CD4 + CD45R+ T lymphocytes in normal individuals and its selective decrease in women with idiopathic thrombocytopenic purpura. Clin Immunol Immunopathol 52:473-85
Ahn, Y S; Rocha, R; Mylvaganam, R et al. (1989) Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med 111:723-9
Mylvaganam, R; Ahn, Y S; Garcia, R O et al. (1989) Very low dose danazol in idiopathic thrombocytopenic purpura and its role as an immune modulator. Am J Med Sci 298:215-20
Mylvaganam, R; Garcia, R O; Ahn, Y S et al. (1988) Depressed functional and phenotypic properties of T but not B lymphocytes in idiopathic thrombocytopenic purpura. Blood 71:1455-60